Biotechnological innovations have vastly improved the capacity to perform large-scale
protein studies, while the methods we have for identifying and quantifying individual proteins …

Disease diagnosis, especially for early diagnosis, is the most effective method to prevent
disease development and mortality. However, low abundance clinical biomarkers in …

Despite major advances in HIV testing, ultrasensitive detection of early infection remains
challenging, especially for the viral capsid protein p24, which is an early virological …

Several neurodegenerative diseases have been linked to proteins or peptides that are
prone to aggregate in different brain regions. Aggregation of amyloid-β (Aβ) peptides is …

Aggregation of amyloid-β peptide (Aβ) is hypothesized to be the primary cause of
Alzheimer's disease (AD) progression. Aβ aggregation has been widely studied using …

Nanopore sensing of proteomic biomarkers lacks accuracy due to the ultralow abundance of
targets, a wide variety of interferents in clinical samples, and the mismatch between pore …

Biological nanopores are increasingly used in molecular sensing due to their single-
molecule sensitivity. The detection of per-and polyfluoroalkyl substances (PFAS) like …

Electrochemistry provides an array of methods to investigate protein aggregation and
determine biomarkers of neurodenenerative diseases. Biosensors detecting monomeric or …

Modern biomedical sensing techniques have significantly increased in precision and
accuracy due to new technologies that enable speed and that can be tailored to be highly …

Prion‐like protein aggregation is characteristic of numerous neurodegenerative diseases,
such as Alzheimer's and Parkinson's diseases. This process involves the formation of …